Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Pulmonary toxicity associated with fludarabine monophosphate.

Literature DB >> 2443463

Pulmonary toxicity associated with fludarabine monophosphate.

P G Hurst¹, M P Habib, H Garewal, M Bluestein, M Paquin, B R Greenberg.

Abstract

Fludarabine monophosphate (FAMP), the 2-fluoro, 5' phosphate derivative of 9-beta-D-arabinofuranosyl adenine (ara-A), is a purine nucleoside antimetabolite presently undergoing clinical testing for the treatment of a variety of malignancies including lymphoproliferative disorders and acute leukemia. We report a case of diffuse interstitial pneumonitis during treatment of chronic lymphocytic leukemia with FAMP. This resolved quickly with high dose steroids, recurred with steroid withdrawal, and abated with further steroid therapy. To our knowledge, this is the first reported case of fludarabine monophosphate associated pulmonary toxicity.

Entities: Chemical Disease

Mesh：

Substances：

Year: 1987 PMID： 2443463 DOI： 10.1007/bf00203548

Source DB: PubMed Journal: Invest New Drugs ISSN： 0167-6997 Impact factor: 3.850

11 in total

1. Busulphan toxicity syndrome caused by chlorambucil.

Authors: M S Rose
Journal: Br Med J Date: 1975-04-19

2. Fatal intraalveolar and interstitial lung fibrosis in chlorambucil-treated chronic lymphocytic leukemia.

Authors: O Refvem
Journal: Mt Sinai J Med Date: 1977 Nov-Dec

3. Pulmonary toxicity induced by mitomycin C is highly responsive to glucocorticoids.

Authors: A Y Chang; J P Kuebler; K J Pandya; R H Israel; B C Marshall; D C Tormey
Journal: Cancer Date: 1986-06-15 Impact factor: 6.860

4. Possible pulmonary effects of alkylating agents.

Authors: F A Rubio
Journal: N Engl J Med Date: 1972-11-30 Impact factor: 91.245

Review 5. Chronic lymphocytic leukemia. Recent advances in biology and treatment.

Authors: R P Gale; K A Foon
Journal: Ann Intern Med Date: 1985-07 Impact factor: 25.391

6. Interstitial pneumonia and chlorambucil.

Authors: P Godard; J P Marty; F B Michel
Journal: Chest Date: 1979-10 Impact factor: 9.410

Review 7. Drug-induced pulmonary disease. Part 1: Cytotoxic drugs.

Authors: J A Cooper; D A White; R A Matthay
Journal: Am Rev Respir Dis Date: 1986-02

8. Phase I and II study of fludarabine phosphate in leukemia: therapeutic efficacy with delayed central nervous system toxicity.

Authors: R P Warrell; E Berman
Journal: J Clin Oncol Date: 1986-01 Impact factor: 44.544

9. Ara-C lung: noncardiogenic pulmonary edema complicating cytosine arabinoside therapy of leukemia.

Authors: H M Haupt; G M Hutchins; G W Moore
Journal: Am J Med Date: 1981-02 Impact factor: 4.965

10. Phase I clinical investigation of 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate (NSC 312887), a new purine antimetabolite.

Authors: J J Hutton; D D Von Hoff; J Kuhn; J Phillips; M Hersh; G Clark
Journal: Cancer Res Date: 1984-09 Impact factor: 12.701

11 in total

1. Lysis pneumonopathy associated with the use of fludarabine phosphate.

Authors: J J Crowley; L Knight; N Charan
Journal: West J Med Date: 1994-12

Review 2. Fludarabine. An update of its pharmacology and use in the treatment of haematological malignancies.

Authors: J C Adkins; D H Peters; A Markham
Journal: Drugs Date: 1997-06 Impact factor: 9.546

Review 3. Management of chronic lymphocytic leukaemia.

Authors: N Kalil; B D Cheson
Journal: Drugs Aging Date: 2000-01 Impact factor: 3.923

4. Phase II study of fludarabine phosphate in multiple myeloma. A Southwest Oncology Group study.

Authors: E H Kraut; J J Crowley; M R Grever; M D Keppen; J D Bonnet; H E Hynes; S E Salmon
Journal: Invest New Drugs Date: 1990-05 Impact factor: 3.850

Review 5. Fludarabine. A review of its pharmacological properties and therapeutic potential in malignancy.

Authors: S R Ross; D McTavish; D Faulds
Journal: Drugs Date: 1993-05 Impact factor: 9.546

Review 6. Fludarabine phosphate. A new anticancer drug with significant activity in patients with chronic lymphocytic leukemia and in patients with lymphoma.

Authors: G Rodriguez
Journal: Invest New Drugs Date: 1994 Impact factor: 3.850

Review 7. Infiltrative lung diseases: complications of novel antineoplastic agents in patients with hematological malignancies.

Authors: Bobbak Vahid; Paul E Marik
Journal: Can Respir J Date: 2008 May-Jun Impact factor: 2.409